Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis
- 29 January 1999
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 38 (2) , 118-125
- https://doi.org/10.1002/(sici)1097-0045(19990201)38:2<118::aid-pros5>3.0.co;2-g
Abstract
BACKGROUND PSP94 (prostate secretory protein of 94 aa; also called PIP), one of the predominant proteins secreted into the seminal fluid, was proposed as an independent diagnostic/prognostic marker for prostate cancers. It was also shown to inhibit rat prostate cancer growth. In this study, we investigated the effect of purified PSP94 on the growth of androgen-independent human prostate cancer cells (PC3) and its potential mechanism of action. METHODS AND RESULTS PSP94, in a dose- and time-dependent manner, inhibited the growth of PC3 cells. The protein demonstrated a stronger inhibitory effect on the colony-forming ability of PC3 cells in soft agar. A daily injection of PSP94 at 5 μg/kg/body weight resulted in a 50–60% inhibition in the growth of PC3 xenografts in athymic mice. PC3 cell growth inhibition by PSP94 resulted from cell death characteristic of morphological apoptosis, which was confirmed by dual fluorescence microscopy, electron microscopy, and DNA fragmentation assays. Mechanistic studies indicated that PSP94 enhanced the expression of proapoptotic protein Bax without affecting Bcl-2 levels. CONCLUSIONS This study suggests that PSP94 may represent a novel, apoptosis-based, antitumor agent applicable to the treatment of hormone-refractory human prostate cancers. Prostate 38:118–125, 1999.Keywords
This publication has 13 references indexed in Scilit:
- Target to apoptosis: A hopeful weapon for prostate cancerThe Prostate, 1997
- A New Scalable Purification Procedure for Prostatic Secretory Protein (PSP94) from Human Seminal PlasmaProtein Expression and Purification, 1996
- Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis.Proceedings of the National Academy of Sciences, 1996
- Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP)Cancer Letters, 1994
- A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell linesCancer Letters, 1993
- Effect of prostatic inhibin peptide (PIP) on prostate cancer cell growth in vitro and in vivoThe Prostate, 1993
- Beta‐microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinomaThe Prostate, 1993
- Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinomaThe Prostate, 1993
- Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostateCancer Letters, 1988
- Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancerThe Prostate, 1987